Cambridge, United Kingdom
CCG.ai, which has been acquired by Dante Labs, champions the mission of delivering data-driven cancer treatment. Established in 2016 and headquartered in the United Kingdom, the company stands at the intersection of biotechnology and health care. Its focus is to harness burgeoning clinical and genomic data to revolutionize cancer treatment, allowing oncologists to make smarter decisions through precision oncology.
The startup made noteworthy progress in biomarker development, aimed at predicting treatment responses. By aligning the correct drug with the right timing, CCG.ai aspires to individualize patient care, significantly optimizing therapeutic outcomes.
In terms of financial backing, CCG.ai secured a $4.50M Seed Round on 31 December 2018, with investment from prominent firms including Soma Capital, Y Combinator, and AME Cloud Ventures. This investment underscored investor confidence in its innovative approach to augmenting cancer treatment efficacy.
